Alternatives to Oseltamivir for Influenza Treatment and Prevention
Introduction to Alternatives
- The American Academy of Pediatrics considers oral oseltamivir the antiviral drug of choice for hospitalized patients with influenza, with zanamivir as an alternative only for non-hospitalized patients without respiratory disease 2, 7
First-Line Alternative: Zanamivir
- Inhaled zanamivir is considered an equally acceptable alternative to oseltamivir for patients who do not have chronic respiratory disease 1, 3
- Zanamivir has shown efficacy rates of 84% in preventing febrile, laboratory-confirmed influenza illness when used for prophylaxis, comparable to oseltamivir's 82% 8, 5
Second-Line Alternative: Peramivir
- Intravenous peramivir is approved for treatment of acute uncomplicated influenza in non-hospitalized patients 2 years and older who have been symptomatic for no more than 2 days 1, 2
- Peramivir is a useful option for patients who cannot absorb oral medications or tolerate inhaled zanamivir 1
Third-Line Alternative: Baloxavir Marboxil
- Oral baloxavir is a selective inhibitor of influenza cap-dependent endonuclease, with a different mechanism of action than neuraminidase inhibitors 1, 2
- Baloxavir is approved for treatment of uncomplicated influenza in people ≥12 years who have been symptomatic for no more than 48 hours 1, 2
Important Considerations
- All neuraminidase inhibitors (oseltamivir, zanamivir, peramivir) and baloxavir have activity against both influenza A and B viruses, unlike older drugs such as amantadine and rimantadine 1, 6
- Treatment should be initiated as early as possible, ideally within 48 hours of symptom onset, to maximize effectiveness 7
Contraindications and Special Populations
- Zanamivir should not be used in patients with underlying respiratory conditions such as asthma or COPD due to risk of bronchospasm 1, 4
- For pregnant women, oseltamivir remains the preferred agent, though data on alternatives are limited 7
- For infants under 1 year, options are very limited - oseltamivir is the only approved agent, with no approved alternatives 9, 7
Antiviral Resistance Considerations
- Continuous monitoring of resistance patterns is conducted by the CDC 3, 4
- In recent seasons, the majority of influenza strains have been susceptible to oseltamivir, zanamivir, and peramivir 3, 4
- High levels of resistance to older drugs (amantadine and rimantadine) persist, so these should not be used unless resistance patterns change significantly 1, 3